S'abonner

IL10 polymorphisms influence neonatal immune responses, atopic dermatitis, and wheeze at age 3 years - 27/02/13

Doi : 10.1016/j.jaci.2012.08.008 
Diana Raedler, PhD a, Sabina Illi, PhD a, Leonardo Araujo Pinto, MD b, Erika von Mutius, MD a, Thomas Illig, PhD c, d, Michael Kabesch, MD e, Bianca Schaub, MD a,
a University Children’s Hospital Munich, Department of Pulmonary and Allergy, LMU Munich, Munich, Germany 
b Instituto de Pesquisas Biomédicas, Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil 
c Institute of Epidemiology, Helmholtz Centre Munich, German Research Centre for Environmental Health, Neuherberg, Germany 
d Hannover Unified Biobank, Hannover Medical School, Hannover, Germany 
e Clinic for Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany 

Corresponding author: Bianca Schaub, MD, University Children’s Hospital Munich, Lindwurmstr 4, 80337 Munich, Germany.

Abstract

Background

IL10 encodes for IL-10, an important anti-inflammatory cytokine with pleiotropic effects. It is crucial for development of immune tolerance, downregulates expression of TH1 cytokines, and is relevant for T-cell regulation. Several IL10 single nucleotide polymorphisms (SNPs) were associated with inflammatory diseases, such as atopic diseases, which might have their onset during early immune maturation.

Objective

We hypothesized that IL10 SNPs are associated with decreased regulatory T (Treg) cell numbers, TH2-skewed immune responses, and decreased IFN-γ levels in cord blood parallel with increased proinflammatory markers, subsequently leading to increased atopic diseases until 3 years.

Methods

Eight genetic IL10 variants, represented by 4 linkage disequilibrium blocks (R2 > 0.80) and 2 distal promoter SNPs, were genotyped in cord blood mononuclear cells of 200 healthy neonates. Cord blood mononuclear cells were cultured unstimulated or after stimulation with lipid A, peptidoglycan, PHA, house dust mite (Der p 1), or Der p 1 plus lipid A. mRNA expression of Treg cell–associated genes (forkhead box protein P3 [FOXP3], glucocorticoid-induced TNF receptor [GITR], lymphocyte activation gene 3 [LAG3]), TH1/TH2 cytokines, TNF-⍺, and GM-CSF were assessed. Atopic and respiratory outcomes (atopic dermatitis [AD] and wheeze) were assessed by means of questionnaire at age 3 years.

Results

Carriers of 3 IL10 SNP blocks and both distal promoter SNPs showed reduced expression of Treg cell markers, reduced IL-5 levels, proinflammatory TNF-⍺ and GM-CSF, and partially increased IFN-γ levels. The same SNPs presented as determinant for AD, wheeze, or symptoms of AD, wheeze, or both at age 3 years.

Conclusions

Polymorphisms in IL10 influenced Treg cell marker expression and TH1/TH2 and proinflammatory cytokine secretion early in life. This was relevant for further development of immune-mediated diseases, such as AD and wheeze, in early childhood.

Le texte complet de cet article est disponible en PDF.

Key words : Atopy, atopic dermatitis, cord blood, cytokines, IL-10, single nucleotide polymorphisms, regulatory T cells, wheeze

Abbreviations used : AD, CBMC, FOXP3, GITR, HWE, LAG3, LD, LpA, Ppg, SNP, TLR, Treg


Plan


 Supported by Bavarian Research Association PIZ-140-08 (to B.S.) and the German Research Foundation as part of the transregional collaborative research program TR22 “allergic immune responses of the lung,” grant DFG SFB TR22/A22 (to D.R. and B.S.). Further funding was provided by the Comprehensive Pulmonary Centre (CPC for B.S.) and by the German Ministry of Education and Research (BMBF) as part of the National Genome Research Network (NGFN), with grant NGFN 01GS0810 (to L.A.P. and M.K.). Genotyping was performed in collaboration with the Genome Analysis Centre of the Helmholtz Centre Munich.
 Disclosure of potential conflict of interest: E. von Mutius is a consultant for Novartis, GlaxoSmithKline, ALK-Abelló, and Protectimmun; has received speakers’ fees from InfectoPharm; has been supported by Airsonnett AB; is a member of the expert panel for the UK Research Excellence Framework; and is an Associate Editor of the Journal of Allergy and Clinical Immunology. M. Kabesch has financial interests in Roxall, GlaxoSmithKline, Novartis, Sanofi Aventis, Allergopharma, and AstraZeneca GmbH and has been supported by Deutsche Forschungsgemeinschaft (DFG), the BMBF, and the European Union (EU). B. Schaub has been supported by DFG and the EU. The rest of the authors declare that they have no relevant conflicts of interest.


© 2012  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 131 - N° 3

P. 789-796 - mars 2013 Retour au numéro
Article précédent Article précédent
  • Atopic sensitization in the first year of life
  • Martin Depner, Markus J. Ege, Jon Genuneit, Juha Pekkanen, Marjut Roponen, Maija-Riitta Hirvonen, Jean-Charles Dalphin, Vincent Kaulek, Susanne Krauss-Etschmann, Josef Riedler, Charlotte Braun-Fahrländer, Caroline Roduit, Roger Lauener, Petra I. Pfefferle, Juliane Weber, Erika von Mutius, PASTURE Study Group ‡
| Article suivant Article suivant
  • Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: A prospective study on the food cause of the disease
  • Alfredo J. Lucendo, Ángel Arias, Jesús González-Cervera, José Luis Yagüe-Compadre, Danila Guagnozzi, Teresa Angueira, Susana Jiménez-Contreras, Sonia González-Castillo, Benito Rodríguez-Domíngez, Livia C. De Rezende, José M. Tenias

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.